Treating Patients With Melanoma and ALK Alterations With Ensartinib
Last updated on July 2021Recruitment
- Recruitment Status
- Active, not recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Melanoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentIntervention Model Description: This single arm, single center, open label Phase 2 trial will utilize a Simon 2 stage design.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03420508
- Collaborators
- Xcovery Holding Company, LLC
- Investigators
- Principal Investigator: Alexander Shoushtari Memorial Sloan Kettering Cancer Center
Get Well Soon